BioVentrix offers benefits to all stakeholders in heart failure:

Physician – become a pioneer to less invasively treat left ventricular heart failure

Patient – improve survival and QoL

Payor – reduce hospitalizations and avoid more expensive, highly invasive procedures like transplant and LVAD

About Us

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

Less Invasive Ventricular Enhancement™ or LIVE™ is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC™ TransCatheter Ventricular Enhancement System is a safer and less invasive alternative compared to a ventricular assist device (VAD) or a heart transplant. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for multidisciplinary heart teams and their patients by its proven clinical improvements.

Our Management Team

Kenneth Miller - President and Chief Executive Officer

President and Chief Executive Officer

Mr. Miller joined BioVentrix in October 2007 as the company’s president and chief executive officer, bringing with him over 30 years of experience in healthcare. He is accomplished at securing financing, setting and executing strategies, and exceeding revenue and profit objectives. Prior to joining BioVentrix, Mr. Miller was vice president of sales and marketing for Cholestech (NASDAQ: CTEC), a global diagnostics company focused on coronary heart disease and diabetes. During his tenure there, Cholestech was acquired by Inverness for $317 million. Prior to that, he served as chief operating officer for R2 Technology, Inc., a diagnostic imaging company that pioneered the use of CAD for mammography. Mr. Miller helped grow revenues from $3 million to $58 million in three years, prior to the company’s acquisition by Hologic, Inc. (NASDAQ: HOLX) in 2006.

He received a Bachelor of Science from Rutgers University, and his MBA with an emphasis in Pharmaceutical Marketing from Farleigh Dickinson University.

William R. Abbott - Chief Financial Officer
Thasee Pillay - Chief Medical Officer
Lon S. Annest, M.D. - Vice President of Medical Affairs
David Schickling - Vice President of Sales and Marketing
Pedro Marques - Vice President of Sales – Europe
Kevin Van Bladel - Sr. Vice President of Product & Therapeutic Development
Noel Messenger - Vice President of Quality, Regulatory Affairs, and Clinical Affairs

Our Board of Directors

Steven Healy

Board Chairman, BioVentrix

Former General Manager, Global Spine, Zimmer Biomet

George Fazio
Kenneth Miller
Warren Pinckert II
Robert Taglich
Mike Taglich
Image

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.

Our News

Contact Us

© 2020 BioVentrix. All Rights Reserved. Powered by MedTech Momentum
The Revivent TC™ trademark is a federally registered trademark owned by BioVentrix. Any unauthorized use is expressly prohibited.